Loading
A phase 2 trial of Venetoclax and Obinutuzumab in chronic lymphocytic leukaemia, run by AbbVie, now recruiting.
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) is a phase 2 interventional study registered as NCT04895436 by AbbVie, with 75 participants planned, started 2022-03-28 and due to reach its primary completion in 2026-11. Interventions recorded: Venetoclax and Obinutuzumab.
Shares BCL-2 inhibitors, Obinutuzumab, AbbVie (incl. ImmunoGen, Capstan), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares BCL-2 inhibitors, Obinutuzumab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares BCL-2 inhibitors, Obinutuzumab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Chronic lymphocytic leukaemia, Monoclonal antibodies and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Chronic lymphocytic leukaemia, Monoclonal antibodies and the tag pipeline.